• -
47 Results
Stem Cell
Unproven Stem Cell-based Interventions: Advancing Policy Through Stakeholder Collaboration
A growing number of stem cell clinics treat a variety of illnesses and injuries, yet few have conducted the necessary clinical research to ensure safety and efficacy. The authors highlight the importance of collaboration between scientists, regulators, patients and patient advocates in developing effective policies and practices for unproven stem cell-based intervention clinics.
Kirstin R.W. Matthews, Ana S. Iltis June 1, 2017
Person looking at graphs and charts
Science Advice in the Trump White House
As his term progresses, President Trump will be faced with a large number of policy challenges, some of them requiring immediate science & technology expertise. In this Science Magazine article, the authors urge the president to consider the Office of Science & Technology Policy, the science advisor and the presidential S&T councils as vital resources that should be used early in the term to drive his policy agenda.
Kirstin R.W. Matthews, Kenneth M. Evans, Neal F. Lane February 10, 2017
US Capitol
A Need for Renewed and Cohesive U.S. Policy on Cord Blood Banking
While the Food and Drug Administration currently regulates storage and use of cord blood (CB) in the United States, other state and federal guidelines on CB education, awareness and ethical considerations remain variable, and no mandatory international guidelines exist. To help organize and coordinate efforts across the United States and other nations, policymakers should implement regulations for high quality standards for both private and public CB banks.
Monica M. Matsumoto, Kirstin R.W. Matthews August 4, 2015
A nurse and a patient smile at each other.
Regulating the Therapeutic Translation of Regenerative Medicine
Regenerative medicine and stem cell research are exciting new fields. But as the fields progress toward clinical therapies, controversies emerge. Hype surrounding stem cell research has caused an increase in their use in interventions that are not clinically proven. Furthermore, the regulatory agencies have a lot of difficulty dealing with cell therapies, which are distinctly different from drugs and medical devices they more commonly approve. To move the field forward, advocates, regulators and scientists need to come together to find new options for stem cell research oversight that protects both the patients and the research field.
Maude Rowland Cuchiara, Jackie Olive, Kirstin R.W. Matthews July 6, 2015